What it is
MOTS-c is a 16 amino acid peptide with an unusual origin. Almost all human proteins are coded in the DNA of the cell nucleus. MOTS-c is coded in the small separate genome inside mitochondria, within the gene for the 12S ribosomal RNA. Its name is short for "mitochondrial open reading frame of the 12S rRNA-c".
It was described in 2015 by Changhan Lee, Pinchas Cohen and colleagues in Cell Metabolism. It belongs to a small family called mitochondrial-derived peptides, alongside humanin. The discovery matters beyond the peptide itself: it suggests mitochondria do not just make energy but also send hormone-like signals to the rest of the body.
How it works
In the 2015 paper, MOTS-c acted mainly on skeletal muscle. Inside cells it inhibited the folate cycle and the purine-building pathway attached to it, and that in turn switched on AMPK, the enzyme that acts as a cell's fuel gauge. AMPK is also activated by exercise, and it shifts cells toward taking up glucose and burning fuel.
Humans produce MOTS-c naturally, and it circulates in the blood.
What the research found
Animal studies
- Lee and colleagues (2015) found that treating mice with MOTS-c prevented both age-related and high-fat-diet-induced insulin resistance, and prevented diet-induced obesity.
- Reynolds and colleagues (2021) gave MOTS-c to young, middle-aged and old mice. Physical performance improved in all age groups. When treatment started in very old mice (about 23.5 months), grip strength, gait and walking capacity improved, which the authors described as a compression of age-related decline.
Human data
- Reynolds and colleagues (2021) also measured MOTS-c in 10 sedentary young men during stationary cycling. Muscle MOTS-c rose about 11.9-fold after exercise and stayed up four hours later. Blood levels rose about 1.6-fold during exercise and returned to baseline within four hours. This shows exercise raises the body's own MOTS-c. It does not show that injecting it does anything.
- CB4211 (analogue). CohBar developed CB4211, a modified MOTS-c, for fatty liver disease and obesity. Its phase 1a/1b trial (NCT03998514) enrolled 88 people and was completed in April 2021. In the phase 1b part, 20 obese adults with fatty liver received 25 mg subcutaneously once daily or placebo for four weeks. The company reported that ALT fell 21% versus a 4% rise on placebo, AST fell 28% versus 11%, and glucose fell 6% versus no change. Liver fat and body weight did not differ significantly from placebo. These figures come from a company press release; ClinicalTrials.gov lists no posted results.
No trial has tested native MOTS-c, the compound sold as a research peptide, in humans.
Side effects reported in studies
The only human safety data comes from the CB4211 analogue. The company reported it was well tolerated with no serious adverse events, with transient mild to moderate injection-site reactions in more than 10% of those treated. Whether this applies to native MOTS-c, which is a different molecule, is unknown. Long-term effects of raising AMPK signalling with an injected peptide have not been studied in people.
MOTS-c vs other mitochondrial compounds
| Compound | Target | Human evidence |
|---|---|---|
| MOTS-c | Folate cycle, AMPK in muscle | Exercise measurement; analogue phase 1 |
| SS-31 | Cardiolipin in the inner mitochondrial membrane | FDA-approved for Barth syndrome |
| NAD+ | Coenzyme for energy and DNA repair | Small trials of oral precursors |
| 5-Amino-1MQ | NNMT enzyme inhibitor | Preclinical |
Some people pair MOTS-c with GLP-1 drugs such as retatrutide on the theory that it offsets fatigue during weight loss. No study has tested that combination.
Status in the Philippines
No MOTS-c product is registered with FDA Philippines, and it is not approved as a medicine anywhere. It is not a controlled substance under RA 9165. Locally it is sold as a research compound and has an audience among Manila's endurance athletes and people on GLP-1 treatment. Anyone with diabetes or prediabetes on glucose-lowering medicine should know that the proposed mechanism overlaps with how those drugs work, which is a conversation for a licensed Philippine physician.
Local stock MOTS-c 10mg at Primara Labs, delivered in Metro Manila and nationwide. Research use only.
Storage
Keep lyophilised MOTS-c refrigerated and away from light. After reconstitution, store at 2 to 8°C. Brownouts are the main risk in Philippine homes: keep vials deep inside the fridge, not in the door, and minimise opening during an outage. See the beginner guide for handling basics.
